Objective To investigate the relationships between several health outcomes in ankylosing spondylitis (AS). Methods Baseline pretreatment data from 214 patients with AS participating in the AS Study for the Evaluation of Recombinant Infl iximab Therapy were analysed. Measures of health-related quality of life (HRQoL) and physical function were used as dependent variables in linear regression analysis. Associations between HRQoL (36-Item Short Form (SF-36)), physical function, clinical disease activity, spinal mobility, structural damage, MRI infl ammation, disease duration, age, gender, body mass index and HLA-B27 were explored. Univariate associations were retested in multivariate models. The robustness of the models was evaluated by sensitivity analyses.
INTRODUCTION
Health outcomes include different aspects of health and illness and their consequences on a person's life. These include health status (symptom severity and degree of functional limitation), impairment (alteration of normal body structure or biofunction), quality of life (subjective appraisal of health status), costs (monetary costs of obtaining care and costs of lost work productivity) and mortality. 1 The Assessment of SpondyloArthritis international Society (ASAS) has recommended a core set of validated ankylosing spondylitis (AS) measures of impairment and health status to be used in clinical trials and clinical practice. 2 -4 Measurement instruments for radiographic damage 5 6 and for MRI infl ammation 7 8 have also been developed and, recently, a new index for measuring disease activity-the AS Disease Activity Score (ASDAS)-was proposed and validated in AS. 9 -11 The spectrum of AS is heterogeneous and the relationships between health outcomes are complex and incompletely understood. Presumably, there is a generic hierarchical order of domains, with health-related quality of life (HRQoL) at the top and signs and symptoms (and MRI infl ammation) at the bottom. HRQoL can be thought of as the highest multidimensional goal dependent on other domains (eg, health status and impairment), refl ecting the overall impact of the illness (including signs and symptoms) and its treatment on patients and their response to these impacts. However, we do not know exactly how these domains interrelate. Improved understanding about these relationships will deepen our knowledge of AS and its management, treatment and impact on patients and society.
This theoretical concept is not new to rheumatic diseases (or to most chronic diseases), and goes back to the writings of Tennant 12 and Fries 13 and to what was to become the International Classifi cation of Impairments, Disabilities, and Handicaps of the World Health Organization. In this schema, as described by Tennant, 12 disease gives rise to impairment, defi ned as 'any loss or abnormality of psychological, physiological, or anatomical structure or function'; impairment itself may lead to disability, defi ned as 'any restriction or lack of ability to perform an activity in the manner or within the range considered normal for a human being'; impairments and disabilities, by interacting with the physical and social environment, can result in handicap, defi ned as a 'disadvantage for the given individual that limits or prevents the fulfi lment of a role that is normal'; and at the end of the diseasehandicap continuum we can fi nd quality of life, a broader outcome that can be infl uenced by a whole series of other factors such as self-esteem, coping skills, age, gender and ethnicity. 12 Despite being a conceptual frame shared between several chronic diseases, the evidence for AS is lacking as the number of previous reports analysing the relationship between outcomes is small, they included small numbers of patients and focused on a limited number of outcomes. A more broad analysis-adjusting for potential confounders and including a large number of health outcomes simultaneously-is lacking, and is of utmost importance as it may offer a more solid conceptual basis for thinking about outcomes in AS and for understanding what we are measuring when assessing patients with this disease. In particular, the availability of infl ammation assessed on MRI of the spine in a large number of patients is a unique feature of the current dataset.
In this study we investigated the relationships between HRQoL, physical function, disease activity, spinal mobility and structural damage in detail and propose a stratifi ed model for health outcomes in AS.
METHODS

AS patient population
This study investigated a representative baseline 80% random sample (224 patients) of the AS Study for the Evaluation of Recombinant Infl iximab Therapy (ASSERT) cohort. 14 Ten patients were excluded from the analysis owing to incomplete radiographic assessment (n=7), incomplete MRI assessment (n=1) or both (n=2). The fi nal number of patients included in this study was 214.
In brief, ASSERT was a double-blind placebo-controlled clinical trial with infl iximab that included patients with AS (according to the modifi ed New York criteria) 15 for at least 3 months prior to screening, with a Bath AS Disease Activity Index (BASDAI) ≥4 (range 0-10) and a Spinal Pain Assessment Score ≥4 (range 0-10 cm, visual analogue scale). Detailed inclusion and exclusion criteria of patients in the ASSERT trial have been described previously. 14 
Measures of health outcomes
Two patient-reported outcomes were used as measures of HRQoL and physical function: the 36-Item Short Form (SF-36) health survey questionnaire 16 (both the SF-36 Physical Component Summary Score (SF-36 PCS) and the SF-36 Mental Component Summary Score (SF-36 MCS)) and the Bath AS Functional Index (BASFI). 17 It should be noted that, although often mislabelled as a quality of life measure, the SF-36 is in fact a health status measure and it should be interpreted as such when we use the term HRQoL.
The BASDAI, 18 the ASDAS 9 -11 and the level of C-reactive protein (CRP) were included as measures of clinical disease activity. Spinal mobility was assessed using the Bath AS Metrology Index (BASMI), 19 -21 structural damage was assessed by the modifi ed Stoke AS Spine Score (mSASSS) 5 6 and MRI spinal infl ammation was assessed by the AS spinal MRI Activity (ASspiMRI-a) score. 7 8 All these measurement tools have been validated and are recommended for use in AS. 4 22 A more detailed description of these well-known outcome measures can be found in the online supplement.
Statistical analysis
All data are expressed as median (IQR) or proportion if applicable. Pearson (normally distributed variables) and Spearman correlation coeffi cients (not normally distributed variables) were used to build a correlation matrix between health outcomes.
Possible associations between BASFI, SF-36 (physical and mental component scores) and a large number of outcome measures (ASDAS, BASDAI, CRP, BASMI, mSASSS, ASspiMRI-a) and clinical-demographic variables (disease duration, age, gender, body mass index (BMI) and HLA-B27) were fi rst explored by univariate linear regression analysis (using SF36-PCS, SF-36 MCS and BASFI as dependent variables). Variables with univariate associations with a p value <0.10 were retested in multivariate models. By default, all multivariate models were adjusted for disease duration, age, BMI and gender.
Separate multivariate models were run using either ASDAS or BASDAI as independent variables (as they represent the same health outcome), and using either mSASSS or BASMI (to avoid collinearity and because we wanted to test if BASMI is an intermediate variable between mSASSS and BASFI). A similar approach (and for the same reasons) was used for BASMI or BASFI as the regressors.
As measures of the strength of the relationship between the models and the dependent variable, we used the R-square (R 2 ) value (the coeffi cient of determination), which is the squared value of the multiple correlation coeffi cient (R) and shows how much variation in the dependent variable is explained by the model. As a further measure of the strength of the model fi t, we used the adjusted R-square (adjR 2 ) value, which compensates for model complexity providing a fairer comparison of multivariate model performance.
Non-normally distributed variables (mSASSS, ASspiMRI-a score, CRP and disease duration) underwent a normalisation procedure based on rank order using the van der Waerden technique before being entered into the linear regression analysis. All tests were two-sided and p values <0.05 were considered statistically signifi cant. Analyses were performed using SPSS Version 16. Table S2 in the online supplement shows the baseline characteristics of the study population. The study population was typical of patients with moderate to severe AS, with poor physical function (median BASFI 5.7), high disease activity (median BASDAI 6.5 and median ASDAS 4.0) and substantial impairment of spinal mobility (median BASMI 4.6). The median SF-36 PCS score (29.5) was well below that of the general population of the USA and Europe (range 49.7-52.7). 23 However, the median SF-36 MCS score (47.1) was in the lower range of that of the general population of the USA and Europe (range 47.6-54.0). 23 Correlation matrix for health outcomes Table 1 Overall, the robustness of the models was lower for SF-36 MCS (adjR 2 =0.07-0.10) compared with SF-36 PCS and BASFI models. An increase of 1 unit in BASMI leads to an estimated aver-6.
RESULTS
Baseline characteristics of the study population
Univariate associations between BASFI, SF-36 PCS, SF-36 MCS and other outcome measures and clinical-demographic variables
age increase of 0.49 in BASFI independent of the effect of ASDAS; similarly, an increase of 1 unit in ASDAS leads to an increase of 0.81 in BASFI ( table 3 ). An increase of 1 unit in BASFI leads to a decrease of 1.7 in SF-36 PCS ( table 4 ) and to a decrease of 1.2 in SF-36 MCS ( table 5 ) , independent of the effect of ASDAS; similarly, an increase of 1 unit in ASDAS leads to a decrease of 2.0 units in SF-36 PCS ( table 4 ) .
DISCUSSION
In a large cohort of patients we have studied the relationships between health outcomes in AS. This analysis showed that physical function is independently determined both by the level of clinical disease activity and by the degree of spinal mobility impairment, and that the physical component of HRQoL is independently determined by physical function and by the level of clinical disease activity. This study also supports the view that spinal mobility is hierarchically an intermediate variable between structural damage and physical function, while physical function itself is intermediate between spinal mobility and the physical component of SF-36.
Combined with a previous analysis of the same cohort showing that spinal mobility impairment in AS is independently determined both by irreversible radiographic spinal damage and by reversible MRI spinal infl ammation, 24 the results from this study allow us to propose a stratifi ed model for health outcomes in AS ( fi gure 1 ). This stratifi ed model endorses the ASAS core set choice of relevant domains, 2 -4 and suggests that the generic domain HRQoL is highest in hierarchy and that all other domains contribute to some extent and independently to HRQoL.
The results were largely similar using either ASDAS or BASDAI as the measurement tool for clinical disease activity, providing further evidence for the validity of the ASDAS as a new measure of disease activity in AS. Some discrepancies were observed for the SF-36 MCS models, where BASFI and BASDAI Table 5 Multivariate linear regression models exploring the independent association between SF-36 MCS (dependent variable) and other clinical and demographic variables were associated with SF-36 MCS to a greater extent than ASDAS. However, SF-36 MCS was still independently determined by ASDAS when BASFI was deleted as regressor. Erythrocyte sedimentation rate was not tested because it was not available in ASSERT, and CRP was not included in the multivariate models because its p value was >0.1 in univariate analysis.
We have estimated the numerical contribution of each variable over the other. This helps to interpret the results of the regression models by giving them a practical meaning. However, we acknowledge that this is a simplifi cation of reality and that the relations we have investigated may not be truly linear but rather curvilinear, as previously suggested by the correlation between damage and mobility which seems to increase with the level of damage. 25 The results from this study are consistent with a previous report 26 showing that physical function in AS is determined by the level of patient-reported disease activity and by the level of radiographic structural damage, in one of the few longitudinal studies addressing health outcomes in AS, with 188 patients included in multivariate analysis. Another longitudinal study 27 looked at 5-year predictors of disability in 212 patients and found that higher age, smoking, less frequent back exercise and worse social support were associated with a poorer functional outcome. However, this study did not adjust for other variables potentially associated with function such as structural damage, spinal mobility and disease activity. At the cross-sectional level, Wanders et al 25 showed acceptable correlations between measures of spinal mobility and measures of structural damage; we have previously shown an independent association between spinal mobility, spinal damage and MRI infl ammation of the spine 24 ; and Almodovar et al 28 described associations between functional capacity and spinal mobility measures. Vesovic-Potic et al 29 reported a negative independent association between the physical functioning domain of SF-36 and BASFI, while Ozdemir 30 showed that all SF-36 domains (except for general health) had signifi cant negative correlations with BASDAI and BASFI scores. However, Turan et al 31 only found a signifi cant negative correlation between the general health domain and BASDAI, and between the role-emotional domain and BASFI.
A limitation of our study is its cross-sectional design. Another limitation is that it is a clinical trial cohort involving patients with severe and active disease. It would be of interest to validate this model in patients with earlier and less severe disease status. However, we analysed a large cohort of patients (n=214) and explored a large number of outcome measures (from MRI infl ammation to HRQoL), adjusting for a number of possible contributing and confounding factors. Such a broad and detailed analysis has never been reported to date. Furthermore, the items used for analysis are generally used in daily clinics and clinical studies. We believe that the associations described here are relevant for the management of patients with AS and may serve as the background model for future longitudinal studies where temporal relationships may be tested. An association does not necessarily imply causation, and only longitudinal studies can evaluate if a change in an outcome measure translates into a subsequent change in the associated measure.
In summary, we have studied in detail the relationships between several AS outcome measures and propose a stratifi ed model for health outcomes in AS. According to this model ( fi gure 1 ), HRQoL is determined by physical function and disease activity, physical function is determined by spinal mobility and disease activity, and spinal mobility is determined by structural damage and infl ammation of the spine. This model explains a large percentage of the variation in the dependent variables, but not the entire variation, suggesting that other variables such as psychological, social, cultural, ethnic and educational factors should also be taken into account in future studies. However, the relationships that we describe are indisputable, are consistent with the conceptual 'continuum of outcome measures' proposed by Tennant and McKenna 12 and suggest that, in order to optimise HRQoL, both physical function and disease activity should be considered major goals in the treatment of AS. They also suggest that optimal physical function-preserving therapy should focus on improving disease activity and also on maintaining spinal mobility which, on its own, requires both the elimination of spinal infl ammation and the prevention of structural damage. This stratifi ed model explains why optimal treatment of AS should be multimodal, involving non-steroidal anti-infl ammatory drugs (NSAIDs) and antitumour necrosis factor (anti-TNF) therapy (drugs that have been shown to improve patient-reported disease activity while, for MRI infl ammation of the spine, the effect is only clear for anti-TNF) as well as therapies more specifi cally addressing spinal mobility (such as physical therapy) and progression of structural damage (such as NSAIDs which have shown to inhibit structural progression independently of infl ammation). 32 As we learn more about how to measure AS, our knowledge about the disease improves and we can make better decisions on how to assess and treat it. The model we propose is useful both for the design and interpretation of clinical trials and also for daily clinical practice, and may contribute to guide best practice in the assessment and treatment of patients with AS. 
